Italy Self-Monitoring Blood Glucose Devices Market Size

Italy Self-Monitoring Blood Glucose Devices Market Analysis

The Italy Self-Monitoring Blood Glucose Devices Market size is estimated at USD 1.20 billion in 2024, and is expected to reach USD 1.30 billion by 2029, growing at a CAGR of 5.92% during the forecast period (2024-2029).

The first year since its inception, the COVID-19 pandemic was responsible for premature deaths, particularly among older individuals. Italy was the first country in Europe affected by COVID-19. Italy was among the countries with the highest mortality rates. Most people who died of COVID-19 were affected by the co-occurrence of two or more chronic conditions in the same individual. Several studies confirmed that chronic diseases like diabetes were associated with adverse outcomes in COVID-19 patients. The pandemic highlighted opportunities for continuing and expanding innovations in the delivery of diabetes care through virtual consultations between healthcare providers and people with diabetes and the use of diabetes technology. Routine diabetes management was essential to mitigate the risk of adverse health outcomes and severe COVID-19 in diabetes patients; however, the pandemic contributed to disruptions in diabetes management.

Blood glucose monitoring increases patients' awareness of glucose values, which supports healthy lifestyle choices. Blood glucose monitoring values help provide feedback and guidance on how to make health behavior changes when needed. Continued elevation in blood glucose levels in diabetes patients can contribute to progressive complications such as renal, nerve, and ocular damage. Appropriate and timely monitoring of blood glucose allows the successful management of out-of-range blood glucose levels, minimizing diabetic-related health complications.

Innovative technologies, such as digital health apps that display and summarize individual blood glucose measurements and incorporate additional relevant data such as insulin doses, meals and snacks, and physical activity, can further support self-management while decreasing disease burden and benefiting overall diabetes care. Integration of blood glucose monitoring with insulin calculators, automated insulin titration software, and remote coaching are further developments that provide patients with poorly controlled diabetes with the additional support needed to improve critical outcomes, thereby enhancing market prospects in the years to come.